A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Thomas Jefferson University
Incyte Corporation
Eilean Therapeutics
Eilean Therapeutics
National Cancer Institute (NCI)
University of Alabama at Birmingham
National Cancer Institute (NCI)
Karyopharm Therapeutics Inc
University of Turin, Italy
Ohio State University Comprehensive Cancer Center
Incyte Corporation
Incyte Corporation
University of Rochester
Merck Sharp & Dohme LLC
Incyte Corporation
M.D. Anderson Cancer Center
Prelude Therapeutics
iOnctura
University of Southern California
City of Hope Medical Center
Incyte Corporation
AbbVie
University Hospital, Brest
Icahn School of Medicine at Mount Sinai
Center for International Blood and Marrow Transplant Research
Novartis
University of Washington
Incyte Corporation
Masonic Cancer Center, University of Minnesota
M.D. Anderson Cancer Center
University of California, Irvine
City of Hope Medical Center
Disc Medicine, Inc
Massachusetts General Hospital
University Hospital, Angers
Karyopharm Therapeutics Inc
Dartmouth-Hitchcock Medical Center
Fred Hutchinson Cancer Center
Azienda Ospedaliero-Universitaria di Parma
Grupo Español de Enfermedades Mieloproliferativas Crónicas PH Negativas
Center for International Blood and Marrow Transplant Research
Washington University School of Medicine
City of Hope Medical Center
Dana-Farber Cancer Institute
University Health Network, Toronto
MPN Research Foundation
Brigham and Women's Hospital
M.D. Anderson Cancer Center
AbbVie
M.D. Anderson Cancer Center